CytoDyn Inc. (OTC: CYDY) Nader Pourhassan, Ph.D, CEO.
CEO Dr. Nader Pourhassan updates investors on the latest developments for CytoDyn’s lead drug candidate, Leronlimab (PRO 140) for use as a Combination Therapy to treat HIV, and expecting FDA approval in early 2020. Dr. Pourhassan also shares what’s ahead for the company’s pipeline for cancer indications
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.